Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $1.7 billion.

  • Gsk's Retained Earnings rose 3466.6% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 3466.6%. This contributed to the annual value of $1.3 billion for FY2024, which is 8503.67% down from last year.
  • Gsk's Retained Earnings amounted to $1.7 billion in Q3 2025, which was up 3466.6% from $1.5 billion recorded in Q2 2025.
  • Gsk's 5-year Retained Earnings high stood at $9.0 billion for Q4 2023, and its period low was $1.2 billion during Q2 2024.
  • For the 5-year period, Gsk's Retained Earnings averaged around $2.6 billion, with its median value being $1.8 billion (2023).
  • As far as peak fluctuations go, Gsk's Retained Earnings soared by 25979.61% in 2023, and later crashed by 8494.32% in 2024.
  • Gsk's Retained Earnings (Quarter) stood at $3.3 billion in 2021, then fell by 24.79% to $2.5 billion in 2022, then skyrocketed by 259.8% to $9.0 billion in 2023, then tumbled by 84.94% to $1.4 billion in 2024, then rose by 29.34% to $1.7 billion in 2025.
  • Its Retained Earnings was $1.7 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.3 billion in Q1 2025.